Michael Barbella, Managing Editor02.29.24
Strategic venture capital firm BioStar Capital has closed its fifth fund at $130.3 million, more than its three previous funds combined.
Led by founder Louis Cannon, M.D., a cardiovascular physician, innovator, and educator, as well as Alan Davis, M.D., orthopedic surgeon, now Emeritus Staff at The Cleveland Clinic, BioStar Capital’s Fund V portfolio includes several established medical device companies:
In a time of declining investments in venture capital, BioStar’s closing overcame current environmental challenges, demonstrating investor confidence in the firm’s model leveraging physician, as well as financial and operational expertise in today’s dynamic healthcare environment. In addition to a commitment to financial returns, BioStar’s mission is to improve patient outcomes in the areas of greatest medical need.
BioStar Capital invests in and nurtures transformative medical technologies in cardiovascular disease, orthopedics, and robotics. The Rocky River, Ohio-based firm has consistently produced life-changing outcomes for patients and rewarding returns for investors.
Led by founder Louis Cannon, M.D., a cardiovascular physician, innovator, and educator, as well as Alan Davis, M.D., orthopedic surgeon, now Emeritus Staff at The Cleveland Clinic, BioStar Capital’s Fund V portfolio includes several established medical device companies:
- Amplitude Vascular Systems, which has developed an intravascular lithotripsy device designed to treat heavily calcified arteries.
- Medical Microinstruments (MMI), which has commercialized a robotic device that permits doctors to operate at microsurgical levels for precision reconstruction of small blood vessels, nerves and lymphatics using the world’s smallest wristed surgical instruments. MMI claims its robot is the only one of its kind currently in operation.
- REVA Medical, developer of the MOTIV Bioresorbable Scaffold, which treats below-the-knee peripheral artery disease and is the first bioresorbable scaffold to obtain CE Mark approval for treating that disease.
- Versa Vascular, which is currently developing a non-tissue, non-mechanical, catheter-delivered implant for treating tricuspid valve regurgitation.
In a time of declining investments in venture capital, BioStar’s closing overcame current environmental challenges, demonstrating investor confidence in the firm’s model leveraging physician, as well as financial and operational expertise in today’s dynamic healthcare environment. In addition to a commitment to financial returns, BioStar’s mission is to improve patient outcomes in the areas of greatest medical need.
BioStar Capital invests in and nurtures transformative medical technologies in cardiovascular disease, orthopedics, and robotics. The Rocky River, Ohio-based firm has consistently produced life-changing outcomes for patients and rewarding returns for investors.